Allergan partners with tribe to fight IPR

In an effort to create a shield against patent challenges under the U.S. Patent and Trademark Office’s inter partes review process, Allergan plc (NYSE:AGN) announced Sept. 8 that it had transferred ownership of six patents covering dry eye drug

Read the full 395 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE